Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-CD47 combination therapy

Anti-CD47 combination therapy

US Patent 11618784 · Granted Apr 4, 2023

Estimated economic value: $88,062,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-CD47 combination therapy2025
Anti-CD47 combination therapy2025
Anti-CD47 combination therapy2025
Combination of lenalidomide and polypeptide construct, and uses thereof2022
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B2021
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B2021
Fusions of antibodies to CD38 and attenuated interferon alpha2021
Fusions of antibodies to CD38 and attenuated interferon alpha2021
Combination of lenalidomide and polypeptide construct, and uses thereof2019
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B2018
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B2018
Antibodies2018